Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2020, with a specific transaction date of December 7, 2020. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of an insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Price | $37.5600 |
| Volume | 1,109.551 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single acquisition event within an executive savings plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed as an acquisition of notional ADSs within Dr. H. Barron's GSK Executive Supplemental Savings Plan account.
Key Facts for Investor Verification
- Insider Identity: Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: Initial notification of an acquisition, not a sale.
- Context: The purchase was made through an Executive Supplemental Savings Plan, indicating a structured compensation or savings mechanism rather than an open-market discretionary trade.
- Financial Impact: The filing does not disclose the total monetary value of the transaction, only the unit price and volume.